Treatment of non-resectable hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue SUPPL. 3, 2002, Pages

  Han, Kwang Hyub ^a   Lee, Jong Tae ^a   Seong, Jinsil ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CISPLATIN; FLUOROURACIL; HOLMIUM 166; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER CELL CARCINOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIOFREQUENCY; TREATMENT OUTCOME;

EID: 0036456873     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.17.s3.39.x     Document Type: Conference Paper

References (35)

1. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330-5.
2. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-8.
3. Bruix J, Llovet JM. Llovet prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.
4. Yamamoto J, Okada S, Shimada K et al. Treatment strategy for small hepatocellular carcinoma: Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001; 34: 707-13.
5. Arii S, Yamaoka Y, Futagawa S et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. Hepatology 2000; 32: 1224-9.
6. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J. Hepatol. 2001; 35: 421-30.
7. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31: 840-5.
8. Ueno S, Tanabe G, Sako K et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 2001; 34: 529-34.
9. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis. 1999; 19: 329-38.
10. Trinchet JC, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J. Hepatol. 1997; 27: 756-65.
11. Okada S. Local ablation therapy for hepatocellular carcinoma. Semin. Liver Dis. 1999; 19: 323-8.
12. Shina S, Tagawa K, Nunuma T. Percutaneous ethanol injection for the treatment of hepatocellular carcinoma. AJR 1990; 154: 947-51.
13. Livraghi T, Giorgio A, Marin G et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-8.
14. Paik YH, Han KH, Lee JT, Lee DY, Chon CY, Moon YM. Treatment of small hepatocellular carcinoma with percutaneous Holmium injection: Comparison with segmental transcatheter arterial embolization (Abstract). J. Gastroenterol. Hepatol. 2000; 15: 11.
15. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-66.
16. Grasso A, Watkinson AF, Tibballs JM, Burroughs AK. Radiofrequency ablation in the treatment of hepatocellular carcinoma: A clinical viewpoint. J. Hepatol. 2000; 33: 667-72.
17. Llovet JM, Vilana R, Brú C et al. Increased risk of tumor seeding after radiofrequency thermal ablation for single hepatocellular carcinoma. Hepatology 2001; 33: 1124-9.
18. Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M, Sugimachi K. Effects of preoperative transcather hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 1993; 72: 3598-608.
19. Bruix J, Llovet JM, Castells A et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83.
20. Pelletier G, Ducreux M, Gay F et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. Groupe CHC. J. Hepatol. 1998; 29: 129-34.
21. Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 1991; 68: 2150-4.
22. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997; 79: 2087-94.
23. Mondazzi L, Bottelli R., Brambilla G et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognosis factors. Hepatology 1994; 19: 1115-23.
24. Dhir V, Swaroop VS, Mohandas KM. Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. Am. J. Clin. Oncol. 1992; 15: 304-7.
25. Stillwagon GB, Order SE, Guse CG et al. 194 Hepatocellular cancers treated by radiation and chemotherapy combinations: Toxicity and response: A Radiation Therapy Oncology Group (RTOG) study. Int. J. Radiat. Oncol. Biol. Phys. 1989; 17: 1223-9.
26. Seong J, Keum KC, Han KH et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1999; 43: 393-7.
27. Seong J, Park HC, Han KH et al. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47: 1331-5.
28. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin-2 in patients with unresectable hepatocellular carcinoma. Hepatology 1989; 10: 349-53.
29. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-6.
30. Chung YH, Song IH, Song BC et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-91.
31. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: Results of treatment with transcatheter oily chemoembolization. AJR 1995; 165: 315-21.
32. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25: 259-62.
33. Okuda S. Transcatheter arterial embolization for advanced hepatocellular carcinoma: The controversy continues. Hepatology 1998; 27: 1743-4.
34. Tanikawa K. Multidisciplinary treatment of hepatocellular carcinoma. In: Tobe T, Kameda H, Okudaira M et al., eds. Primary Liver Cancer in Japan. Tokyo: Springer-Verlag, 1992; 327-34.
35. Lazzaroni S, Livraghi T. Multimodality treatment. In: Livraghi T, Makuuchi M, Buscarini L, eds. Diagnosis and Treatment of Hepatocellular Carcinoma. London: Greenwich Medical Media 1997; 401-13.